logo

For the Inventor, By the Inventor

Tucson, AZ, United States of America

Klaus Brendel

This inventor holds 21 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Cell Pathways, The University of Arizona, Fgn, Inc.. Active years: 1989-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus Brendel. Retrieved from https://idiyas.com/inventor/klaus-brendel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 21

% Patents Active = 95.2

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 665(Granted Patents)


Location History:

  • Tucson, AZ (US) (1989 - 2002)
  • Tuscon, AZ (US) (1999 - 2003)

Company Filing History:

goldMedal16 out of 75 
 
Cell Pathways
 patents
silverMedal8 out of 1,062 
 
The University of Arizona
 patents
bronzeMedal1 out of 1 
 
Fgn, Inc.
 patent
4. 1 out of 224 
 
University Patents, Inc.
 patents
5. 2 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1989-2003

Loading Chart...
Areas of Expertise:
Neoplasia
Hydroxamic Acids
Extracellular Matrix
Benzylidene
Indenyl Compounds
Cryo-Preservation
Lactone Compounds
Pyrrole Acetic Acids
Acetamides
Ureas
Propionamides
Tissue Slices
21 patents (USPTO):Explore Patents
1. 6610854 - Substituted condensation products of N-benzyl-3-indenylacentamides with heterocyclic aldehydes for neoplasia (2003-08-26),
2. 6426349 - Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia (2002-07-30),
3. 6403831 - Substituted benzylidene indenyl formamides, acetamides and propionamides (2002-06-11),
4. 6300346 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions (2001-10-09),
5. 6166053 - Substituted condensation products of N-benzyl-3-idenylacetamides with (2000-12-26),
6. 6121321 - Substituted methoxy benzylidene indenyl acetic and propionic acids for (2000-09-19),
7. 6071934 - Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating (2000-06-06),
8. 6066634 - Substituted condensation products of N-benzyl-3-indenylacetamides (2000-05-23),
9. 6063818 - Substituted benzylidene indenyl formamides, acetamides and propionamides (2000-05-16),
10. 6028116 - Substituted condensation products of 1H-indenyl-hydroxyalkanes with (2000-02-22),
11. 5998477 - Substituted methoxy benzylidene indenyl-acetic and propionic acids for (1999-12-07),
12. 5965619 - Method for treating patients having precancerous lesions with (1999-10-12),
13. 5948779 - Substituted condensation products of n-benzyl-3-indenyl acetamides with (1999-09-07),
14. 5776962 - Lactone compounds for treating patient with precancerous lesions (1998-07-07),
15. 5721347 - Esters and amides of substituted pyrrole acetic acids (1998-02-24),

Title: Klaus Brendel: Innovator in Neoplasia Research

Introduction

Klaus Brendel is a notable inventor based in Tucson, AZ, with an impressive portfolio of 21 patents. His work primarily focuses on the development of compounds that have significant medical applications, particularly in the field of oncology.

Latest Patents

Among his latest innovations, Klaus has patented the "Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia." This invention highlights compounds that are instrumental in inducing or promoting apoptosis and halting the proliferation of uncontrolled neoplastic cells. These compounds are particularly beneficial for the treatment of neoplasia, which includes both precancerous and cancerous lesions.

Career Highlights

Klaus Brendel has had a remarkable career, with significant contributions to the scientific community. He has worked with notable institutions such as Cell Pathways and the University of Arizona, where he has applied his expertise in creating impactful medical innovations.

Collaborations

Throughout his career, Klaus has collaborated with esteemed colleagues such as Rifat Pamukcu and Paul Gross. These collaborations have likely fostered innovative thinking and led to advancements in their joint research efforts.

Conclusion

In conclusion, Klaus Brendel's contributions through his patents and collaborations have significantly advanced the field of neoplasia research. His innovative work continues to inspire and pave the way for new treatments and therapies in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…